Salarius Pharmaceuticals Files 8-K

Ticker: DCOY · Form: 8-K · Filed: Jul 14, 2025 · CIK: 1615219

Sentiment: neutral

Topics: 8-K, corporate-filing, financials

TL;DR

Salarius Pharma filed an 8-K on 7/14, reporting events as of 7/10. Standard filing.

AI Summary

Salarius Pharmaceuticals, Inc. filed an 8-K on July 14, 2025, reporting other events and financial statements as of July 10, 2025. The company, formerly known as Flex Pharma, Inc., is based in Houston, TX, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing indicates ongoing corporate reporting and potential updates regarding Salarius Pharmaceuticals' financial status or other material events.

Risk Assessment

Risk Level: low — This is a routine 8-K filing reporting standard corporate events and financial statements, not indicating immediate significant risk.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported in this 8-K filing?

The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.

What is the significance of the 'Financial Statements and Exhibits' being reported?

This indicates that the filing includes updated financial information and supporting documents for Salarius Pharmaceuticals, Inc.

When was Salarius Pharmaceuticals, Inc. formerly known as Flex Pharma, Inc.?

The date of the name change from Flex Pharma, Inc. to Salarius Pharmaceuticals, Inc. was July 30, 2014.

What is the primary business of Salarius Pharmaceuticals, Inc.?

Salarius Pharmaceuticals, Inc. operates in the 'Pharmaceutical Preparations' industry, with SIC code 2834.

What is the principal executive office address for Salarius Pharmaceuticals, Inc.?

The principal executive offices are located at 2450 Holcombe Blvd. Suite X, Houston, TX 77021.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 14, 2025 regarding Salarius Pharmaceuticals, Inc. (DCOY).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing